Please use this identifier to cite or link to this item:
|Title:||Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients|
|Keywords:||Cancer and noncancer Asian patients|
|Citation:||Lee, H.S., Goh, B.C., Fan, L., Khoo, Y.M., Wang, L., Lim, R., Ong, A.B., Chua, C. (2003-03-01). Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients. British Journal of Clinical Pharmacology 55 (3) : 270-277. ScholarBank@NUS Repository. https://doi.org/10.1046/j.1365-2125.2003.01767.x|
|Abstract:||Aims: To investigate CYP3A activity in cancer and noncancer Asian patients using midazolam and to reveal possible alternative traits for phenotyping CYP3A. Methods: Intravenous midazolam 2.5 mg or 2.5-8 mg was administered to 27 cancer and 24 noncancer patients, respectively. Plasma was sampled at 0, 0.25, 0.5, 1, 1.5, 2, 3.5 and 5 h after intravenous ultrashort, 30 s infusion. Plasma midazolam and 1′-hydroxymidazolam concentrations were determined using GCMS. The disposition of midazolam and 1′-hydroxymidazolam in these patients was compared. Midazolam clearance was correlated with dose-normalized plasma midazolam concentrations (concentration/per dose). Results: Clearance (CL) and steady state volume of distribution (Vss) of midazolam (mean ± SD, 95% confidence level) in cancer (424 ± 155, 61.3 ml min-1; 1.21 ± 0.46, 0.18 l kg-1) and noncancer (407 ± 135, 57.1 ml min-1; 1.15 ± 0.33, 0.155 l kg-1) patients, respectively, were not different and comparable with published data. Clearance variability was 4-5 fold in both groups. Midazolam clearance correlated significantly with all plasma concentration/per dose at and after the 1-h time point, with a minimum correlation coefficient of r = 0.752, P < 0.001. Conclusions: CYP3A activities determined with different doses of midazolam in cancer and noncancer Asian patients showed variability of 4-5-fold and were not different between groups. One to two-fold plasma midazolam concentrations per dose may be feasible as a simple alternative phenotypic trait for hepatic CYP3A activity determination.|
|Source Title:||British Journal of Clinical Pharmacology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Aug 16, 2018
WEB OF SCIENCETM
checked on Jul 23, 2018
checked on May 18, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.